CorMedix (CRMD) shares were up over 20% in recent trading on Tuesday after its Q1 net income and revenue surpassed analysts' consensus.
The company reported Q1 results swung to net income Tuesday of $0.30 per diluted share, from a loss of $0.25 a year earlier.
Analysts polled by FactSet expected EPS of $0.26.
Revenue for the quarter ended March 31 was $39.1 million.
Analysts surveyed by FactSet expected $36.9 million.
CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million.
As of March 31, the company said it had $77.5 million in cash and/or cash equivalents on hand, and expected it could fund operations for at least 12 months from the issuance of its quarterly report on From 10-Q.
Price: 10.92, Change: +1.89, Percent Change: +20.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。